David A. Siegel Rhythm Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 3,300 shares of RYTM stock, worth $328,053. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,300
Previous 9,700
65.98%
Holding current value
$328,053
Previous $612,000
45.59%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding RYTM
# of Institutions
282Shares Held
486MCall Options Held
498KPut Options Held
150K-
Perceptive Advisors LLC New York, NY419MShares$41.7 Billion94.44% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$670 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.68MShares$565 Million9.85% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$557 Million4.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA5MShares$497 Million0.01% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $5.54B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...